HOME >> MEDICINE >> NEWS
New project to analyze why Polycystic Ovary Syndrome and insulin resistance are so closely linked

Understanding the link between Polycystic Ovary Syndrome (PCOS) and insulin resistance is the aim of a new project announced today, funded by the charity WellBeing of Women.

It is known that women with PCOS have a 3-fold increase in their risk of developing type-2 diabetes, where the body does not produce enough insulin or cannot use insulin properly. Insulin resistance is an important factor in the condition, which is the most common female hormone disorder. PCOS affects between 5 and 10 per cent of women and is a major cause of infertility.

The new 97K project aims to identify a defective point on the insulin signalling pathway in women with PCOS. The researchers, from Imperial College London, hope this will enable the development of new therapies which target this part of the pathway, to counter the insulin resistance and the fertility problems that PCOS can cause.

Insulin is released from cells in the pancreas after eating and it signals insulin-sensitive tissues (such as fat and muscle) to take up glucose, keeping glucose levels in the bloodstream normal. In people with insulin resistance, normal amounts of insulin are not adequate to produce a normal glucose response, meaning that levels of insulin in the bloodstream need to be higher to achieve normal blood sugar levels.

Insulin resistance (and/or the compensatory excess of insulin in the bloodstream), may contribute to abnormalities in function of the ovaries that lead to many of the symptoms of PCOS. These include irregular periods, or no periods at all; fertility problems; weight gain; acne; and excessive hair growth (hirsutism).

A longer term concern is that insulin resistance also predisposes people to diabetes. In some patients the pancreas is unable, in the long-term, to produce enough insulin to compensate for the resistance of the tissues to insulin action. Consequently, blood sugar levels rise. What is not known is why PCOS and insulin resista
'"/>

Contact: Laura Gallagher
L.Gallagher@imperial.ac.uk
44-020-759-46702
Imperial College London
12-Mar-2007


Page: 1 2

Related medicine news :

1. Test project of patient-centered medical home model endorsed by American College of Physicians
2. Spanish project AmIVital creates intelligent communication devices for elderly and disabled people
3. Healthy schools project gets an A
4. Liverpool launches 20 million project to develop medicines for children
5. New family health history projects focus on Alaska Native, Appalachian communities
6. ESSP launches project on the effects of global environmental change on human health
7. Global Environmental Change and Human Health: New project launched at GEC Conference in Beijing
8. Clean water project hit by funding drought
9. $500,000 grant launches health literacy project to benefit older adults
10. St. Jude projects 90 percent cure rate for ALL
11. Virtual microscopy project wins educational technology award

Post Your Comments:
(Date:4/17/2014)... signs of chronic inflammation in non-cancerous prostate tissue may ... cancer than those with no inflammation, according to results ... Johns Hopkins Kimmel Cancer Center. , The link between ... with so-called high-grade prostate cancer those with a ... presence of the most aggressive and rapidly growing prostate ...
(Date:4/17/2014)... a study published today in PLOS Pathogens , ... malaria is common can mount an immune response to ... avoid repeated bouts of high fever and illness and ... bloodstream. The findings may help researchers develop future interventions ... malaria parasite. , Each year, approximately 200 million cases ...
(Date:4/17/2014)... In a review published in the April issue of ... The Feinstein Institute for Medical Research, says it,s time ... approach to treating sepsis, which kills millions ... Sepsis occurs when molecules released into the bloodstream to ... body. Inflammation is necessary for maintaining good health ...
(Date:4/17/2014)... Doctors who treat patients with a severe and ... an agonizing treatment decision. , The drug sirolimus ... relieve shortness of breath. But some patients eventually ... potentially fatal complications following transplantation. , "It,s a ... director of Loyola University Medical Center,s LAM Clinic ...
(Date:4/17/2014)... By discovering a new mechanism that allows blood to ... UC Irvine and the Salk Institute have opened the ... stroke-induced brain damage. , A complex and devastating neurological ... primary reason for disability in the U.S. The blood-brain ... blood-borne material into the brain, causing the permanent deficits ...
Breaking Medicine News(10 mins):Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Study sheds light on how the immune system protects children from malaria 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:Study IDs new cause of brain bleeding immediately after stroke 2
(Date:1/15/2014)...  Zafgen, Inc., a leading biopharmaceutical company dedicated to ... today announced initial results from its Phase 2a ... aminopeptidase 2 (MetAP2), in patients with Prader-Willi syndrome ... results showed improvements in body weight, hunger-related behaviors, ...
(Date:1/14/2014)... 2014 HeartWare International, Inc . (NASDAQ: ... miniaturized circulatory support technologies that are revolutionizing the treatment ... revenues for the fourth quarter of 2013 will be ... approximately $208 million. "Our full-year revenue growth ...
(Date:1/14/2014)... 14, 2014 InformEx, North America,s ... chemistry, will hold the 30 th edition of its ... Convention Center from January 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ... pharmaceutical, fine chemical and specialty chemical companies will take part ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
Cached News: